These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32131689)

  • 21. Guideline-recommended secondary prevention drug therapy after acute myocardial infarction: predictors and outcomes of nonadherence.
    Bauer T; Gitt AK; Jünger C; Zahn R; Koeth O; Towae F; Schwarz AK; Bestehorn K; Senges J; Zeymer U;
    Eur J Cardiovasc Prev Rehabil; 2010 Oct; 17(5):576-81. PubMed ID: 20351550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adherence to recommendations for secondary prevention medications after myocardial infarction in Estonia: comparison of real-world data from 2004 to 2005 and 2017 to 2018.
    Lõiveke P; Marandi T; Ainla T; Fischer K; Eha J
    BMC Cardiovasc Disord; 2021 Oct; 21(1):505. PubMed ID: 34670499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: baseline results from the STABILITY study.
    Vedin O; Hagström E; Stewart R; Brown R; Krug-Gourley S; Davies R; Wallentin L; White H; Held C
    Eur J Prev Cardiol; 2013 Aug; 20(4):678-85. PubMed ID: 22496275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determinants of adherence to evidence-based therapy after acute myocardial infarction.
    Hamood H; Hamood R; Green MS; Almog R
    Eur J Prev Cardiol; 2016 Jun; 23(9):975-85. PubMed ID: 26198723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. No gender differences in prognosis and preventive treatment in patients with AMI without significant stenoses.
    Hansen KW; Hvelplund A; Abildstrøm SZ; Prescott E; Madsen M; Madsen JK; Jensen JS; Thuesen L; Thayssen P; Tilsted HH; Jørgensen E; Galatius S
    Eur J Prev Cardiol; 2012 Aug; 19(4):746-54. PubMed ID: 21724682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Post-myocardial Infarction (MI) Care: Medication Adherence for Secondary Prevention After MI in a Large Real-world Population.
    Huber CA; Meyer MR; Steffel J; Blozik E; Reich O; Rosemann T
    Clin Ther; 2019 Jan; 41(1):107-117. PubMed ID: 30591287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries.
    Kotseva K; Wood D; De Bacquer D; De Backer G; Rydén L; Jennings C; Gyberg V; Amouyel P; Bruthans J; Castro Conde A; Cífková R; Deckers JW; De Sutter J; Dilic M; Dolzhenko M; Erglis A; Fras Z; Gaita D; Gotcheva N; Goudevenos J; Heuschmann P; Laucevicius A; Lehto S; Lovic D; Miličić D; Moore D; Nicolaides E; Oganov R; Pajak A; Pogosova N; Reiner Z; Stagmo M; Störk S; Tokgözoğlu L; Vulic D;
    Eur J Prev Cardiol; 2016 Apr; 23(6):636-48. PubMed ID: 25687109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of adherence to evidence-based therapy after acute myocardial infarction on all-cause mortality.
    Hamood H; Hamood R; Green MS; Almog R
    Pharmacoepidemiol Drug Saf; 2015 Oct; 24(10):1093-104. PubMed ID: 26183333
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Organisational determinants of adherence to secondary prevention medications after acute myocardial infarction].
    Perrone E; Lenzi J; Avaldi VM; Castaldini I; Protonotari A; Rucci P; Piccinni C; Morini M; Fantini MP
    Epidemiol Prev; 2015; 39(2):106-14. PubMed ID: 26036739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is non-HDL-cholesterol a better predictor of long-term outcome in patients after acute myocardial infarction compared to LDL-cholesterol? : a retrospective study.
    Wongcharoen W; Sutthiwutthichai S; Gunaparn S; Phrommintikul A
    BMC Cardiovasc Disord; 2017 Jan; 17(1):10. PubMed ID: 28056802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term medication adherence in patients with ST-elevation myocardial infarction and primary percutaneous coronary intervention.
    Reuter H; Markhof A; Scholz S; Wegmann C; Seck C; Adler C; Michels G; Hoepp HW; Baldus S; Pfister R
    Eur J Prev Cardiol; 2015 Jul; 22(7):890-8. PubMed ID: 24938277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Timing of First Postdischarge Follow-up and Medication Adherence After Acute Myocardial Infarction.
    Faridi KF; Peterson ED; McCoy LA; Thomas L; Enriquez J; Wang TY
    JAMA Cardiol; 2016 May; 1(2):147-55. PubMed ID: 27437885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Higher risk of major adverse cardiac events after acute myocardial infarction in patients with schizophrenia.
    Attar R; Wester A; Koul S; Eggert S; Polcwiartek C; Jernberg T; Erlinge D; Andell P
    Open Heart; 2020 Sep; 7(2):. PubMed ID: 32994353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unsatisfactory risk factor control and high rate of new cardiovascular events in patients with myocardial infarction and prior coronary artery disease.
    Jortveit J; Halvorsen S; Kaldal A; Pripp AH; Govatsmark RES; Langørgen J
    BMC Cardiovasc Disord; 2019 Mar; 19(1):71. PubMed ID: 30922234
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of medication adherence on clinical outcomes of coronary artery disease: A meta-analysis.
    Du L; Cheng Z; Zhang Y; Li Y; Mei D
    Eur J Prev Cardiol; 2017 Jun; 24(9):962-970. PubMed ID: 28436725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medication adherence, biological and lifestyle risk factors in patients with myocardial infarction: a ten-year follow-up on socially differentiated cardiac rehabilitation.
    Hald K; Larsen FB; Nielsen KM; Meillier LK; Johansen MB; Larsen ML; Christensen B; Nielsen CV
    Scand J Prim Health Care; 2019 Jun; 37(2):182-190. PubMed ID: 31122102
    [No Abstract]   [Full Text] [Related]  

  • 37. Secondary prevention of coronary artery disease in contemporary clinical practice.
    Jankowski P; Czarnecka D; Wolfshaut-Wolak R; Łysek R; Łukaszewska A; Bogacki P; Grodecki J; Mirek-Bryniarska E; Nessler J; Podolec P; Kawecka-Jaszcz K; Pająk A
    Cardiol J; 2015; 22(2):219-26. PubMed ID: 25299500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adherence to agents acting on the renin-angiotensin system in secondary prevention of non-fatal myocardial infarction: a self-controlled case-series study.
    Ortolani P; Di Bartolomeo S; Marino M; Vagnarelli F; Guastaroba P; Rapezzi C; De Palma R
    Eur Heart J Cardiovasc Pharmacother; 2015 Oct; 1(4):254-9. PubMed ID: 27532449
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Medication use in long-term survivors from the MONICA/KORA Myocardial Infarction Registry.
    Amann U; Kirchberger I; Heier M; Thilo C; Kuch B; Meisinger C
    Eur J Intern Med; 2018 Jan; 47():62-68. PubMed ID: 28826823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predicted impact of lipid lowering therapy on cardiovascular and economic outcomes of Swedish atherosclerotic cardiovascular disease guideline.
    Journath G; Hambraeus K; Hagström E; Pettersson B; Löthgren M
    BMC Cardiovasc Disord; 2017 Aug; 17(1):224. PubMed ID: 28814290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.